Invesco Ltd. Has $251.32 Million Stock Position in DaVita Inc. (NYSE:DVA)

Key Points

• Invesco Ltd. increased its stake in DaVita Inc. by 3.4% during the 1st quarter, owning approximately 2.14% of the company, valued at $251.32 million.
• DaVita's stock has seen a recent 2.3% increase, currently priced at $132.08, with a 52-week range between $126.07 and $179.60.
• The company reported a quarterly EPS of $2.95, surpassing expectations and indicating a revenue increase of 6.1% year-over-year.

Invesco Ltd. grew its position in DaVita Inc. (NYSE:DVA - Free Report) by 3.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,642,947 shares of the company's stock after acquiring an additional 53,402 shares during the period. Invesco Ltd. owned about 2.14% of DaVita worth $251,322,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Koss Olinger Consulting LLC bought a new position in shares of DaVita in the 1st quarter valued at about $649,000. Measured Wealth Private Client Group LLC increased its holdings in shares of DaVita by 29.4% during the 1st quarter. Measured Wealth Private Client Group LLC now owns 3,221 shares of the company's stock worth $493,000 after acquiring an additional 732 shares during the last quarter. National Bank of Canada FI increased its holdings in shares of DaVita by 30.8% during the 1st quarter. National Bank of Canada FI now owns 53,791 shares of the company's stock worth $8,230,000 after acquiring an additional 12,666 shares during the last quarter. Y.D. More Investments Ltd acquired a new position in shares of DaVita during the 1st quarter worth approximately $35,000. Finally, Arjuna Capital acquired a new position in shares of DaVita during the 1st quarter worth approximately $1,269,000. Institutional investors own 90.12% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on DVA shares. Truist Financial set a $148.00 target price on DaVita in a report on Friday, August 8th. Wall Street Zen raised DaVita from a "hold" rating to a "buy" rating in a report on Friday, April 25th. Finally, Barclays decreased their target price on DaVita from $169.00 to $160.00 and set an "equal weight" rating on the stock in a report on Thursday, August 7th.

Insider Activity

In other news, insider James O. Hearty sold 2,351 shares of the stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $150.00, for a total transaction of $352,650.00. Following the sale, the insider directly owned 26,038 shares of the company's stock, valued at approximately $3,905,700. This represents a 8.28% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 1.50% of the company's stock.

DaVita Stock Performance

NYSE DVA traded up $0.96 on Friday, reaching $135.35. The stock had a trading volume of 721,001 shares, compared to its average volume of 925,075. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.39 and a quick ratio of 1.34. The firm has a fifty day moving average of $139.68 and a two-hundred day moving average of $145.28. DaVita Inc. has a 1-year low of $126.07 and a 1-year high of $179.60. The company has a market cap of $9.68 billion, a P/E ratio of 13.31, a price-to-earnings-growth ratio of 0.97 and a beta of 1.09.

DaVita (NYSE:DVA - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $2.95 EPS for the quarter, beating analysts' consensus estimates of $2.70 by $0.25. DaVita had a return on equity of 369.39% and a net margin of 6.35%. The firm had revenue of $3.38 billion for the quarter, compared to analyst estimates of $3.36 billion. During the same period in the prior year, the firm posted $2.00 EPS. The company's revenue for the quarter was up 6.1% on a year-over-year basis. On average, equities research analysts anticipate that DaVita Inc. will post 10.76 EPS for the current year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.